From Proteopedia
proteopedia linkproteopedia link
Better Known as: Crixivan
Mechanism of Action
Pharmacokinetics
| HIV Protease Inhibitor Pharmacokinetics[1][2][3][4][5][6][7][8][9][10]
|
| Parameter
| Ritonavir
| Tipranavir
| Indinavir
| Saquinavir
| Amprenavir
| Fosamprenavir
| Lopinavir
| Darunavir
| Atazanavir
| Nelfinavir
|
| Tmax (hr)
| 4.4
| ~3
| 1.5
| Saquinavir
| .98
| Fosamprenavir
| 2
| .5
| 2-4
| Nelfinavir
|
| Cmax (ng/ml)
| 13120
| 14600
| 8100
| 1540
| 4901
| Fosamprenavir
| 11.9
| 2730
| ~4393
| 4381
|
| Bioavailability (%)
| Ritonavir
| Tipranavir
| 65
| 4
| Amprenavir
| Fosamprenavir
| Lopinavir
| Darunavir
| 68
| Nelfinavir
|
| Protein Binding (%)
| 99
| >99
| 61
| 98
| 90
| 90
| 99
| 95
| 86
| 98
|
| T1/2 (hr)
| 4.8
| 4.2
| 1.2
| 4.5
| 5.5
| 7.7
| 6.1
| 29.4
| 5.3
| 3.3
|
| AUC (ng/ml/hr)
| 128100
| 46500
| 20900
| 16200
| 11999
| Fosamprenavir
| 117600
| 4746
| ~26045
| 27000
|
| Clearance (L/h)
| Ritonavir
| 32.4
| Indinavir
| 36.7
| 56.8
| Fosamprenavir
| 1.7
| Darunavir
| Atazanavir
| Nelfinavir
|
| Dosage (mg)
| 600
| 600
| 800
| 1000
| 600
| 700
| 280
| 400
| 400
| 750
|
| Metabolism
| Hepatic (CYP3A4 & CYP2C19)
| Hepatic (CYP3A4)
| Hepatic (CYP3A4)
| Hepatic (CYP3A4 & CYP3A5)
| Hepatic (CYP3A4)
| Hepatic (CYP3A4)
| Hepatic (CYP3A4)
| Hepatic (CYP3A4)
| Hepatic (CYP3A4)
| Hepatic (CYP3A4)
|
Drug Resistance
The biggest difficulty with treating HIV is the rapidity at which it mutates and becomes resistant to treatments. To view a comprehensive and interactive analysis of the mutations which confer drug resistance to HIV Protease, See: HIV Protease Inhibitor Resistance Profile
References
- ↑ Goebel FD, MacGregor TR, Sabo JP, Castles M, Johnson PA, Legg D, McCallister S. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients. HIV Clin Trials. 2010 Jan-Feb;11(1):28-38. PMID:20400409 doi:10.1310/hct1101-28
- ↑ Ferry et al, United States Patent US6147095, Pharmacia & Upjohn Company.
- ↑ L. Veronese et al. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function. Antimicrob Agents Chemother. 2000 April; 44(4): 821–826.
- ↑ J. Ford, et al. Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients. Antimicrob Agents Chemother. 2004 July; 48(7): 2388–2393.
- ↑ Remmel RP, Kawle SP, Weller D, Fletcher CV. Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma. Clin Chem. 2000 Jan;46(1):73-81. PMID:10620574
- ↑ Fuster D, Clotet B. Review of atazanavir: a novel HIV protease inhibitor. Expert Opin Pharmacother. 2005 Aug;6(9):1565-72. PMID:16086644 doi:10.1517/14656566.6.9.1565
- ↑ Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, Raoof A. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos. 2009 Apr;37(4):809-20. Epub 2009 Jan 8. PMID:19131522 doi:10.1124/dmd.108.024109
- ↑ von Moltke LL, Durol AL, Duan SX, Greenblatt DJ. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol. 2000 Jun;56(3):259-61. PMID:10952482
- ↑ Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther. 2005 Dec;78(6):605-18. PMID:16338276 doi:10.1016/j.clpt.2005.08.014
- ↑ Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J, Gorowara M, Phasomsap C, Jupimai T, Boonrak P, Pancharoen C, Burger D, Ruxrungtham K. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. J Antimicrob Chemother. 2009 Nov;64(5):1080-6. Epub 2009 Sep 2. PMID:19729375 doi:10.1093/jac/dkp322
